Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 594

Sort by

Sort Order Select

Journal Articles

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Muneyoshi Futami, MD PhD, Keisuke Suzuki, MS, Satomi Kato, BS, Yoshio Tahara, MS, Yoichi Imai, MD PhD, Takayuki Mimura, PhD, Yoshihiro Watanabe, PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 2067.

https://doi.org/10.1182/blood-2019-129601

Published: 2019

Journal Articles

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, Ajibade O Ashaye, MD MBA, MPH, MSc., Ruchit Shah, PhD, Shelby Corman, PharmD, MS, BCPS, Mehul Dalal, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 3482.

https://doi.org/10.1182/blood-2019-127289

Published: 2019

Journal Articles

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Mingci Cai, MD, Shu Cheng, MD PhD, Wang Xin, PhD, Jianda Hu, PhD, Yongping Song, Zixun Yan, Yujie Jiang, MD, Xiaosheng Fang, PhD, Xiaoyun Zheng, Lihua Dong, Mengmeng Ji, Li Wang, MD PhD, Pengpeng Xu, Weili Zhao

Blood (2019) 134 (Supplement_1): 1556.

https://doi.org/10.1182/blood-2019-122369

Published: 2019

Journal Articles

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

Shin Lee, MD, Negoro Eiju, Morishita Tetsuji, MD PhD, Kei Fujita, MD, Hideaki Yamauchi, MD, Kana Oiwa, MD, Takanori Ueda, MD PhD, Takahiro Yamauchi, MD PhD

Blood (2019) 134 (Supplement_1): 2902.

https://doi.org/10.1182/blood-2019-121527

Published: 2019

Journal Articles

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

James Yeung, MBBS, Ashlea Campbell, BSc MBBS FRACP FRCPA, Christian E Bryant, MBBS PhDFRACP FRCPA, Liane Khoo, MBBS PhDFRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Harry J Iland, MBBS FRACP FRCPA MHGSA, Stephen R Larsen, MBBS PhDFRACP FRCPA, Susan Moreton, MBBS FRACP FRCPA, Douglas E Joshua, BSc(Hons) MBBS DPhil FRACP FRCPA, Vinay Vanguru, MBBS FRACP FRCPA, Derek A McCulloch, BSc MBBChir PhDFRACP FRCPA, Danny Hsu, MBBS FRACP FRCPA, John Gibson, MBBS PhDFRACP FRCPA, P. Joy Ho, MBBS DPhil FRACP FRCPA, Christina Brown, MBBS PhDFRACP FRCPA

Blood (2019) 134 (Supplement_1): 2911.

https://doi.org/10.1182/blood-2019-131589

Published: 2019

Journal Articles

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

Waleed Ghanima, MD PhD, Marc Michel, Abderrahim Khelif, Bernadette Darne, Pal André Holme, PhDMD

Blood (2019) 134 (Supplement_1): 2358.

https://doi.org/10.1182/blood-2019-126975

Published: 2019

Journal Articles

Antibody-Associated Autoimmune Disease (AAD) in Children with Cancer in Immune Recovery Phase Following Cessation of Chemotherapy

Akihiro Iguchi, MD PhD, Kazuya Hara, MD, Yukayo Terashita, MD, Minako Sugiyama, MD, Yuko Cho, MD, Atsushi Manabe, MD PhD

Blood (2019) 134 (Supplement_1): 1052.

https://doi.org/10.1182/blood-2019-123015

Published: 2019

Journal Articles

The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

Lamya Garabet, Pal André Holme, PhDMD, Bernadette Darne, Abderrahim Khelif, Tor Henrik Anderson Tvedt, MD, Marc Michel, Waleed Ghanima, MD PhD

Blood (2019) 134 (Supplement_1): 4892.

https://doi.org/10.1182/blood-2019-126974

Published: 2019

Journal Articles

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Blood (2019) 134 (Supplement_1): 350.

https://doi.org/10.1182/blood-2019-126798

Published: 2019

Journal Articles

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Nadav Ofshenko, Eyal Bercovich, Tania Mashiach, Michal Weiler-Sagie, Daniela Militianu, Eldad J Dann, MD

Blood (2019) 134 (Supplement_1): 4042.

https://doi.org/10.1182/blood-2019-122675

Published: 2019

Journal Articles

Interim Serum Soluble Interleukin-2 Receptor Levels Are Strongly Associated with Prognosis in Newly Diagnosis DLBCL Patients

Haruya Okamoto, MD, Akihiro Miyashita, MD, Hiroaki Nagata, MD, Yasuhiko Tsutsumi, MD PhD, Yuri Kamitsuji, MD PhD, Yutaka Kobayashi, MD PhD, Nobuhiko Uoshima, MD PhD

Blood (2019) 134 (Supplement_1): 4118.

https://doi.org/10.1182/blood-2019-122375

Published: 2019

Journal Articles

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Blood (2019) 134 (Supplement_1): 4073.

https://doi.org/10.1182/blood-2019-122948

Published: 2019

Journal Articles

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-Versus-Host Disease with Prednisone and Everolimus (PredEver first): A Prospective Multicenter Phase IIa Study

Francis Ayuketang Ayuk, MD, Eva Maria Wagner, MD, Daniel Wolff, MD, Stephanie von Harsdorf, MD, Christian Koenecke, MD, Herbert G. Sayer, MD PhD, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 4523.

https://doi.org/10.1182/blood-2019-129801

Published: 2019

Journal Articles

Clonal Dynamics and Publicness of CMV-Specific TCR Repertoire after Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 4551.

https://doi.org/10.1182/blood-2019-122894

Published: 2019

Journal Articles

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

Ga-Young Song, Seok Jin Kim, MD PhD, Sang Eun Yoon, Jin Seok Kim, MD PhD, Ho-Young Yhim, MD PhD, Youngil Koh, MD PhD, Sung Yong Oh, MD PhD, Ho Sup Lee, MD PhD, Ho-Jin Shin, MD PhD, Young Rok Do, MD PhD, Won Sik Lee, MD PhD, Lee Gyeong-Won, Dae Sik Kim, Yong Park, Deok-Hwan Yang, MD PhD

Blood (2019) 134 (Supplement_1): 4002.

https://doi.org/10.1182/blood-2019-126574

Published: 2019

Journal Articles

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

German Alejandro Detarsio, Sr., BSc, Mariana Raviola, Mauro Davoli, MD, Maria Fabiana Garcia

Blood (2019) 134 (Supplement_1): 4936.

https://doi.org/10.1182/blood-2019-125977

Published: 2019

Journal Articles

Megakaryocyte Morphological Classification Based Predictive Model for Steroid Sensitivity in Primary Immune Thrombocytopenia

Mixue Xie, Jingjing Zhu, Yanlong Zheng, Xueying Li, Xianbo Huang, MD PhD, Xiujin Ye, MD PhD

Blood (2019) 134 (Supplement_1): 4911.

https://doi.org/10.1182/blood-2019-123627

Published: 2019

Journal Articles

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Eliza A Hawkes, Kate Manos, MBBS, Charmaine Smith, Joanne Hawking, Stephanie O'Brien, Leonid Churilov, Joseph McKendrick, William Renwick, Andrew Grigg, Tom Witkowski, Andrew Scott, Sze-Ting Lee, Wendi Lin, Chun Fong, Carmela Rooney, Allison Barraclough, Joel Wight, Geoff Chong

Blood (2019) 134 (Supplement_1): 5332.

https://doi.org/10.1182/blood-2019-127858

Published: 2019

Journal Articles

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Akira Honda, MD PhD, Yu Oyama, MD, Kazuhiro Toyama, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 5492.

https://doi.org/10.1182/blood-2019-129324

Published: 2019

Journal Articles

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Sarah R Brown, PhD MSc, BSc, Andrew Hall, Jessica Kendall, BSc, MSc, Emma Ingleson, Louise Flanagan, PhD, Holger W Auner, MD PhD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Mamta Garg, MD FRCP, FRCPath, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 5552.

https://doi.org/10.1182/blood-2019-123672

Published: 2019

NARROW

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

The Effect of Diagnostic Wait Time on the Survival of Patients with Diffuse Large B-Cell Lymphoma Differs Depending on International Prognostic Index

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

Antibody-Associated Autoimmune Disease (AAD) in Children with Cancer in Immune Recovery Phase Following Cessation of Chemotherapy

The Risk of Thromboembolism Associated with Treatment of ITP with Rituximab: Adverse Event Reported in Two Randomized Controlled Trials

Favorable Outcomes of Newly Diagnosed Intravascular Large B-Cell Lymphoma Patients Treated with R-CHOP Combined with High-Dose Methotrexate Plus Intrathecal Chemotherapy: Results from a Multicenter Phase 2 Trial (PRIMEUR-IVL)

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Interim Serum Soluble Interleukin-2 Receptor Levels Are Strongly Associated with Prognosis in Newly Diagnosis DLBCL Patients

Rituximab and Bendamustine for First-Line Treatment of Frail or Elderly Patients with Aggressive B-Cell Lymphoma: Final Results of the Prospective Phase-II Brenda Trial of GLA (German Lymphoma Alliance)

Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-Versus-Host Disease with Prednisone and Everolimus (PredEver first): A Prospective Multicenter Phase IIa Study

Clonal Dynamics and Publicness of CMV-Specific TCR Repertoire after Allogeneic Stem Cell Transplantation

Prognostic Significance of Interim PET/CT Assessment for the Treatment of Advanced Stage of Marginal Zone Lymphoma in the Post Immunochemotherapy Era

"a Needle in a Haystack". Let´s Talk about Acquired Hemophilia in Pediatrics

Megakaryocyte Morphological Classification Based Predictive Model for Steroid Sensitivity in Primary Immune Thrombocytopenia

AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Bortezomib Overcomes Poor Prognosis Conferred By High Sictp in Untreated Plasma Cell Disorders

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only